Taiga Biotechnologies important milestone
Optimapharm is pleased to announce we have reached an important milestone on Taiga Biotechnologies Inc. TBX-2400-01 study initiating first site in Croatia for patients undergoing hematopoietic stem cell transplant (HSCT).
#teamOptimapharm is excited for continuation of collaboration with Taiga Biotechnologies and proud to support them in the fight against blood cancers.
Read the full article at: https://www.prnewswire.com/news-releases/taiga-initiates-phase-12-clinical-study-of-tbx-2400-in-acute-myeloid-leukemia-and-myelofibrosis-in-croatia-301420845.html
For more information about clinical trial please visit: https://clinicaltrials.gov/ct2/show/NCT04709458?term=taiga+biotechnologies&draw=2&rank=1